HOUSTON, TEXAS December 4, 2019 ImmunoMet Therapeutics, a clinical stage biotechnology company targeting cellular metabolism to develop novel anti-tumor and anti-fibrotic therapies, today announced that it will be participating and presenting at the 2020 Biotech Showcase Investor Conference at the Hilton San Francisco Union Square, San Francisco, CA. Benjamin Cowen, PhD, MBA, ImmunoMet’s President and CEO will present an overview of the Company on January 14, 2020 at 9:45 AM (PT). He will also be available for private meetings with investors and potential partnering collaborators on the Company’s novel anti-tumor and anti-fibrotic therapies from January 13 through January 15, 2020. About Biotech Showcase Now in its twelfth year, Biotech Showcase™ is an investor conference, during JPM 2020, devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. About ImmunoMet Therapeutics
ImmunoMet is a clinical stage biotech targeting cellular metabolism to develop novel anti-tumor and anti-fibrotic therapies. ImmunoMet’s lead molecule, IM156, is an OXPHOS inhibitor with demonstrated impressive in-vivo efficacy in resistant solid tumors. IM156 is currently in Phase 1 with a good safety profile and is expected to progress into Phase 2 in 2020. ImmunoMet has initiated a second program in fibrosis and owns a large library of biguanides with the potential to develop, or partner, new products. The company was founded in 2015, is headquartered in the Houston JLABs near MD Anderson, and has raised $19M to date.  For more information about the company, please visit www.immunomet.com.